Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial looked at a product called Norflo Oro compared to a placebo (a dummy treatment with no active ingredient) in people with a specific type of eye inflammation called HLA-B27 uveitis. A total of 49 people were enrolled — 25 in the Norflo Oro group and 24 in the placebo group. Of those, 18 in the Norflo Oro group and 23 in the placebo group completed the full 12-month study. The main thing the trial was measuring was whether the number of uveitis flare-ups (episodes where the eye inflammation returned) changed over the 12 months of the study compared to the 12 months before it started. The reported data shows that, on average, people in the Norflo Oro group had 0.35 flare-ups per person during the study period, while people in the placebo group had 0.58 flare-ups per person. Both figures represent a change from each group's starting point before the trial began. The trial also tracked eye pressure (measured in mmHg — a standard unit for pressure) as a secondary measure. The reported data shows small changes in eye pressure in both groups, though the full details across all measurement points were not straightforwardly separated in the submitted data, so those figures should be interpreted with caution. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 35353651) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Early Phase 1 Uveitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with a type of eye inflammation (uveitis) linked to a specific genetic marker called HLA-B27
- Your eye inflammation is currently not in an active flare-up (non-acute phase)
- You have had at least one previous episode of this eye inflammation returning
Who may not be able to join:
- You have taken supplements, vitamins, or any anti-inflammatory, immune-suppressing, or biological medicines for your eye condition in the last 30 days
- It is expected that you will need to take anti-inflammatory medicines during the study period
- You have had any injections into or around the eye area in the past 6 months
- You are currently on long-term treatment with anti-inflammatory or immune-suppressing medicines
- You are a woman who is currently using hormonal contraceptives (such as the pill), are pregnant, or are breastfeeding
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in Mean Number of Uveitis Relapses Per Patient Between the 12 Month Study Period Compared to Baseline
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.